Obesity
Conditions
Brief summary
Evaluation of the diagnostic performance of an algorithm developed to detect metabolic profiles specific of non-alcoholic steatohepatitis NASH and based on the reading of a blood sample's infrared spectra
Detailed description
The study is aimed at patients suffering from severe or morbid obesity and engaged in a bariatric surgery course. An additional blood sample will be taken upstream of the surgical procedure in the fasted subject. The metabolic fingerprint of the patient will be analyzed on serum from spectral data measured at most two hours after collection. The spectra obtained by the spectroscopy platform will be processed by algorithmic analysis to build the diagnostic test. During the surgical procedure, a liver biopsy will be performed. The sample will be sent to the pathology laboratory for preparation and the slides will then be anonymized to be sent to a specialized laboratory for centralized reading by an expert pathologist. This expert will determine the diagnosis of non-alcoholic steatohepatitis (NASH) or non-NASH after microscopic analysis of the sample without having any information about the patient. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
Interventions
DIAGNOSTIC_TESTNASHMIR
An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
Sponsors
Clinact
Diafir
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Intervention model description
The study is aimed at patients suffering from severe or morbid obesity and engaged in a bariatric surgery course. An additional blood sample will be taken upstream of the surgical procedure in the fasted subject. During the surgical procedure, a liver biopsy will be performed. The two diagnosis determined by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years old; * Patient able to read, write and understand the French language; * Patient who has signed an informed consent form before carrying out any procedure related to the study; * Patient supported in bariatric surgery; * Patient affiliated to a social security scheme or comparable scheme
Exclusion criteria
* Patient who has already benefited from a bariatric surgery (ring, sleeve, bypass ..); * Patient taking: corticosteroid for more than 2 months, amiodarone, methotrexate, tamoxifen, 5-fluorouracil, irinotecan, cisplatin, asparaginase, nucleoside reverse transcriptase inhibitors of HIV, tetracycline, valproic acid, perhexilline; * Patient with excessive alcohol consumption (\> 210 g/week in men,\> 140 g/week in women) present or past; * Patient with infection or coinfection present or passed with hepatitis B virus, hepatitis C virus or human immunodeficiency virus; * Patient with known chronic liver disease (including hemochromatosis, autoimmune hepatitis ...); * pregnant, parturient or nursing women; * Patient deprived of liberty by judicial or administrative decision; * Patient subject to a legal protection measure;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance | 0-12 months | The comparison of the results obtained by the mathematical analysis of the infrared spectra with those obtained by the reference method on histological samples from liver biopsies will allow to classify the results in true-positive, false-positive, true-negative and false-negative. The diagnostic performance of the signature will be evaluated by calculating the sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio values. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance considering current weight | 0-12 months | Diagnostic performance of the test taking into account current weight (kg). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering weight of the patient at the age of 20 | 0-12 months | Diagnostic performance of the test taking into account Weight of the patient at the age of 20 (kg). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering body mass index | 0-12 months | Diagnostic performance of the test taking into account BMI (Body Mass Index) (kg/m2). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering waist | 0-12 months | Diagnostic performance of the test taking into account waist (cm). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering hip circumference | 0-12 months | Diagnostic performance of the test taking into account Hip circumference (cm). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering systolic blood pressure | 0-12 months | Diagnostic performance of the test taking into account systolic blood pressure (mmHg). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering diastolic blood pressure | 0-12 months | Diagnostic performance of the test taking into account diastolic blood pressure (mmHg). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering type 2 diabetes | 0-12 months | Diagnostic performance of the test taking into account type 2 diabetes (yes/No). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering sleep apnea | 0-12 months | Diagnostic performance of the test taking into account sleep apnea (Yes/No). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering alcohol consumption | 0-12 months | Diagnostic performance of the test taking into account current and/or previous alcohol consumption (Date and number of drinks per week). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering tobacco consumption | 0-12 months | Diagnostic performance of the test taking into account current and/or previous tobacco consumption (date and number of pack of cigarettes per year). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering coffee consumption | 0-12 months | Diagnostic performance of the test taking into account coffee consumption (number of cups per day). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering cannabis consumption | 0-12 months | Diagnostic performance of the test taking into account cannabis consumption (number of joints per week). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the hemoglobin concentration | 0-12 months | Diagnostic performance of the test taking into account the hemoglobin concentration (g/100mL). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the mean corpuscular volume | 0-12 months | Diagnostic performance of the test taking into account mean corpuscular volume (fL). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the leukocyte count | 0-12 months | Diagnostic performance of the test taking into account leukocyte count (Giga/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering size | 0-12 months | Diagnostic performance of the test taking into account size (cm). Significance of each clinical parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant clinical variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of aspartate transaminase | 0-12 months | Diagnostic performance of the test taking into account aspartate transaminase (UI/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of alanine aminotransferase | 0-12 months | Diagnostic performance of the test taking into account alanine aminotransferase (UI/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of gamma-glutamyl transferase | 0-12 months | Diagnostic performance of the test taking into account the concentration of gamma-glutamyl transferase (UI/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of bilirubin | 0-12 months | Diagnostic performance of the test taking into account the concentration of bilirubin (mg/dL). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of alkaline phosphatase | 0-12 months | Diagnostic performance of the test taking into account the concentration of alkaline phosphatase (UI/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the prothrombin time | 0-12 months | Diagnostic performance of the test taking into account the prothrombin time (%). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the blood glucose level | 0-12 months | Diagnostic performance of the test taking into account the blood glucose level (mmol/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the HbA1c level | 0-12 months | Diagnostic performance of the test taking into account the HbA1c level (hemoglobin A1c) (%). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of total cholesterol | 0-12 months | Diagnostic performance of the test taking into account the concentration of total cholesterol (mmol/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of HDL cholesterol | 0-12 months | Diagnostic performance of the test taking into account the concentration of HDL cholesterol (mmol/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of LDL cholesterol | 0-12 months | Diagnostic performance of the test taking into account the concentration of LDL cholesterol (mmol/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of triglycerides | 0-12 months | Diagnostic performance of the test taking into account the concentration of triglyceride (mmol/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of C reactive protein | 0-12 months | Diagnostic performance of the test taking into account the concentration of C reactive protein (mg/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of ferritin | 0-12 months | Diagnostic performance of the test taking into account the concentration of ferritin (g/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the concentration of albumin | 0-12 months | Diagnostic performance of the test taking into account the concentration of albumin (g/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
| Diagnostic performance considering the subtype of non-alcoholic steatohepatitis determined through analysis of biopsy samples | 0-12 months | Diagnostic performance of the test according to the different subtypes of non-alcoholic steatohepatitis (NAS score). NAFLD Activity Score calculated according to the steatosis grade (0, 1, 2 or 3), level of lobular inflammation (0, 1, 2 or 3) and stages of liver cell injury (0, 1 or 2) |
| Diagnostic performance considering the platelet count | 0-12 months | Diagnostic performance of the test taking into account platelet count (Giga/L). Significance of each biological parameter will be assessed using statistical tests (mean comparison) on the two main populations (Non Alcoholic Steato Hepatitis Yes or No). Using logistic regression, a score calculated with significant biological variables will be aggregated to spectral score (primary outcome) in order to assess new diagnostic performance. |
Countries
Belgium
Outcome results
None listed